121 related articles for article (PubMed ID: 8866927)
1. Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol.
Clark DJ; Lipworth BJ
Br J Clin Pharmacol; 1996 Mar; 41(3):247-9. PubMed ID: 8866927
[TBL] [Abstract][Full Text] [Related]
2. Lung delivery of salbutamol by dry powder inhaler (Turbuhaler) and small volume antistatic metal spacer (Airomir CFC-free MDI plus NebuChamber).
Lipworth BJ; Clark DJ
Eur Respir J; 1997 Aug; 10(8):1820-3. PubMed ID: 9272925
[TBL] [Abstract][Full Text] [Related]
3. Clinical equivalence of a novel non-chlorofluorocarbon-containing salbutamol sulfate metered-dose inhaler and a conventional chlorofluorocarbon inhaler in patients with asthma.
Dockhorn R; Vanden Burgt JA; Ekholm BP; Donnell D; Cullen MT
J Allergy Clin Immunol; 1995 Jul; 96(1):50-6. PubMed ID: 7622763
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of Salbutamol Delivered from the Unit Dose Dry Powder Inhaler: Comparison with the Metered Dose Inhaler and Diskus Dry Powder Inhaler.
Moore A; Riddell K; Joshi S; Chan R; Mehta R
J Aerosol Med Pulm Drug Deliv; 2017 Jun; 30(3):164-172. PubMed ID: 28170282
[TBL] [Abstract][Full Text] [Related]
5. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study.
Houghton CM; Langley SJ; Singh SD; Holden J; Monici Preti AP; Acerbi D; Poli G; Woodcock A
Br J Clin Pharmacol; 2004 Oct; 58(4):359-66. PubMed ID: 15373928
[TBL] [Abstract][Full Text] [Related]
6. Comparative lung delivery of salbutamol given via Turbuhaler and Diskus dry powder inhaler devices.
Lipworth BJ; Clark DJ
Eur J Clin Pharmacol; 1997; 53(1):47-9. PubMed ID: 9349929
[TBL] [Abstract][Full Text] [Related]
7. Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
Lipworth BJ; Clark DJ
Pulm Pharmacol Ther; 1997 Aug; 10(4):211-4. PubMed ID: 9695144
[TBL] [Abstract][Full Text] [Related]
8. Relative bioavailability of salbutamol to the lung following inhalation via a novel dry powder inhaler and a standard metered dose inhaler.
Hindle M; Peers EM; Parry-Billings M; Chrystyn H
Br J Clin Pharmacol; 1997 Mar; 43(3):336-8. PubMed ID: 9088593
[TBL] [Abstract][Full Text] [Related]
9. Dry powder inhalers are bioequivalent to metered-dose inhalers. A study using a new urinary albuterol (salbutamol) assay technique.
Hindle M; Newton DA; Chrystyn H
Chest; 1995 Mar; 107(3):629-33. PubMed ID: 7874928
[TBL] [Abstract][Full Text] [Related]
10. Review of therapeutically equivalent alternatives to short acting beta(2) adrenoceptor agonists delivered via chlorofluorocarbon-containing inhalers.
Hughes DA; Woodcock A; Walley T
Thorax; 1999 Dec; 54(12):1087-92. PubMed ID: 10567628
[TBL] [Abstract][Full Text] [Related]
11. Lung bioavailability of generic and innovator salbutamol metered dose inhalers.
Clark DJ; Gordon-Smith J; McPhate G; Clark G; Lipworth BJ
Thorax; 1996 Mar; 51(3):325-6. PubMed ID: 8779143
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vivo lung delivery of hydrofluoroalkane-salbutamol formulation via metered-dose inhaler alone, with plastic spacer, or with cardboard tube.
Fowler SJ; Wilson AM; Griffiths EA; Lipworth BJ
Chest; 2001 Apr; 119(4):1018-20. PubMed ID: 11296163
[TBL] [Abstract][Full Text] [Related]
13. Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol.
Chrystyn H
Br J Clin Pharmacol; 1996 Aug; 42(2):257-8. PubMed ID: 8864330
[No Abstract] [Full Text] [Related]
14. Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica.
Cheng YS; Fu CS; Yazzie D; Zhou Y
J Aerosol Med; 2001; 14(2):255-66. PubMed ID: 11681657
[TBL] [Abstract][Full Text] [Related]
15. Systemic concentrations of salbutamol and HFA-134a after inhalation of salbutamol sulfate in a chlorofluorocarbon-free system.
Harrison LI; Cline A; Wells TM; Jacobson JP; Cooper KM; Chang SF; Nelson JR; Ekholm BP; Morganroth J
Ther Drug Monit; 1996 Jun; 18(3):240-4. PubMed ID: 8738762
[TBL] [Abstract][Full Text] [Related]
16. Determination of the relative bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance manufactured by supercritical fluids and micronization.
Richardson CH; de Matas M; Hosker H; Mukherjee R; Wong I; Chrystyn H
Pharm Res; 2007 Nov; 24(11):2008-17. PubMed ID: 17510755
[TBL] [Abstract][Full Text] [Related]
17. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects.
Chrousos GP; Ghaly L; Shedden A; Iezzoni DG; Harris AG
Chest; 2005 Jul; 128(1):70-7. PubMed ID: 16002918
[TBL] [Abstract][Full Text] [Related]
18. Moving from CFC aerosol to HFA aerosol or dry powder inhalers: what do patients think?
Hartung TK; Allbutt H; Dewar M; Innes JA; Crompton GK
Respiration; 2002; 69(4):314-9. PubMed ID: 12169743
[TBL] [Abstract][Full Text] [Related]
19. The equivalent bronchodilator effects of salbutamol formulated in chlorofluorocarbon and hydrofluoroalkane-134a metered dose inhalers on the histamine-induced pulmonary response in dogs.
Nogami-Itoh M; Yakuo I; Hammerbeck DM; Miller RL; Takeyama K
Pharm Res; 1997 Feb; 14(2):208-12. PubMed ID: 9090711
[TBL] [Abstract][Full Text] [Related]
20. Lung delivery of non-CFC salbutamol via small volume metal spacer and large volume plastic spacer devices compared with an open vent jet nebulizer.
Lipworth BJ; Clark DJ
Br J Clin Pharmacol; 1998 Feb; 45(2):160-3. PubMed ID: 9491830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
